Top Pharma List methodology page

• The Top Pharma List is based on data provided by research and consulting firm GlobalData.
• The current version of the data ranks companies based on information from GlobalData Pharma Intelligence Center’s Sales Analytics Database, as shown on October 3, 2024.
• Figures for the period 2024-30 are a forecast, but only show the performance of those companies featured in the 2023 ranking.

US/Japan/Europe Rx

• These lists rank the top companies based on geographic-specific sales.

Products

• Product sales are mapped to the parent company, rather than subsidiary companies, as they are reported in the annual reports of the parent company itself.
• For example, ViiV Healthcare (whose partners include Pfizer and Shionogi) operates as a subsidiary of GSK, so sales for ViiV’s Triumeq have been attributed to GSK.
• Similarly, Xtandi is attributed to Astellas not Pfizer and Imbruvica is attributed to AbbVie rather than Johnson & Johnson.
• Finally, sales of Eliquis are reported separately by both Bristol-Myers Squibb and Pfizer and so appears twice in the top product ranking, as does Enbrel with sales as reported by Amgen and Pfizer.

Therapy area sales

• The sales data provided are not indication-specific where drugs are approved, or in development, for multiple indications. Instead they’re based on GlobalData’s Key Therapy Area classification, which places products into a single therapeutic area based on its corporate positioning and/or mechanism of action.
• However, product sales may contribute to more than one sales segment, eg biologics and oncology, in which can sales segments for a company may add up to more than its total sales.